Last reviewed · How we verify
Lumigan 0.03% Unit Dose
At a glance
| Generic name | Lumigan 0.03% Unit Dose |
|---|---|
| Also known as | Bimatoprost 0.3mg/ML |
| Sponsor | Laboratoires Thea |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose (PHASE4)
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (PHASE1, PHASE2)
- Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study) (PHASE4)
- Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study) (PHASE4)
- Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study (PHASE4)
- Safety and Efficacy of a Drug Delivery System in Glaucoma (PHASE2)
- Bimatoprost in the Treatment of Eyelash Hypotrichosis (PHASE3)
- Efficacy of Changing to DUOTRAV® From Prior Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lumigan 0.03% Unit Dose CI brief — competitive landscape report
- Lumigan 0.03% Unit Dose updates RSS · CI watch RSS
- Laboratoires Thea portfolio CI